including the aflibercept and denosumab BPCIA litigation, and the various challenges to the Inflation Reduction Act’s Drug Price Negotiation Program. Stay tuned for the latest updates.

Today, Benzinga 's options scanner spotted 28 uncommon options trades for Amgen. This isn't normal. The overall sentiment of ...

In the following chart, we are able to follow the development ... in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered ...

Teva Pharmaceutical Industries TEVA reported fourth-quarter 2024 adjusted earnings of 71 cents per share, which beat the ...

By embracing these opportunities, Life sciences companies can not only avoid getting caught in a riptide but chart new ... its antibody drug conjugate (ADC), and SPD8, a denosumab biosimilar ...

Dividend Payout Ratio: 40% to 60%. The dividend payout ratio is the portion of a company’s after-tax earnings to pay shareholders dividends. The healthy range starts from 30% to about 50%, but today, ...

As Sandoz gears up to launch one of the most anticipated biosimilars of the year, the company could face near-term ...

Risks include Prolia's patent expiration and potential litigation impacts on BLINCYTO, but promising pipeline assets are expected to offset these challenges. Amgen Inc. (NASDAQ:AMGN) is a ...

The following bupropion dosage chart highlights the basics, including the typical starting dose and the maximum or largest dose of bupropion per day. All doses are listed in milligrams (mg).

Dr. Reddy's Lab is poised to witness crosswinds from a drop in revenue from the patent expiration of Revlimid and increased ...